Research Reports

Key takeaways

Mr. Allan J. Camaisa intends to allow his director term to expire at the 2026 annual stockholder meeting.

Camaisa's decision resulted from no disagreement with Company operations, policies or practices.

Board reduced size from six to five directors effective on 2026 annual stockholder meeting date.

Board eliminated Class III director vacancy following Camaisa's notice.

Scott Leftwich appointed to Audit Committee effective April 1, 2026.

Full analysis

The planned departure of director Allan J. Camaisa at the 2026 annual stockholder meeting is routine, as it aligns with the natural expiration of his term without any noted conflicts over company matters. This prompted the Board to proactively reduce its size from six to five members by eliminating the resulting Class III vacancy, in line with the Company's Bylaws. Additionally, Scott Leftwich's immediate appointment to the Audit Committee on April 1, 2026, ensures continuity in oversight functions. These governance adjustments signal orderly board refreshment without disruption to leadership stability.

CLDI · Calidi Biotherapeutics, Inc.

Summary

Key takeaways

Full analysis